Brilinta Taiwan Post Approval Safety Study
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 108 participants.
Also called NCT02406248
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 108 participants
- Sponsor
- Registry
-
NCT02406248
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Taiwan
- Registry status
- Completed
Technical summary
Registry record NCT02406248. Allocation not applicable; no masking; primary purpose treatment. Start 2015-04-23 (actual); primary completion 2017-02-09 (actual). Results posted on 2018-10-15.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Brilinta Taiwan Post Approval Safety Study
- Condition
- Non ST-elevation Myocardial Infarction
- Intervention (Drug)
- Ticagrelor 180mg loading dose taken orally, followed by 90mg twice daily (bd)
- Lead sponsor
- AstraZeneca
Record details
- Record id
cardio:ct-nct02406248- Content hash
a3a07fb1a4aa5d4b32aa730a9a6ed7194055c6a2466995ac0ac02c17ed8c6d0c